Although FGFR2 amplification is expected to be a new therapeutic target for advanced gastric cancer [25–28], a recent randomized phase II study comparing the efficacy of AZD4547 versus paclitaxel for advanced gastric cancer with FGFR2 amplification or polysomy did not show any significant benefits in the AZD4547 arm [39]. This evidence concerns the gene FGFR2 and gastric cancer.